Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.66 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944119 | 0.87 | ADORA1 (0.48) | ADORA1ALDH1A1POLBSMN1; SMN2 | |
| Iodide SCHEMBL3994386 | 0.84 | ADORA1 (0.47) | ADORA1FBP1ALDH1A1POLBGAA | |
| SCHEMBL13944118 | 0.83 | ADORA1 (0.45) | ADORA1FBP1ALDH1A1POLBGAA | |
| Iodide SCHEMBL4618850 | 0.80 | ADORA1 (1.00) | ADORA1FBP1 | |
| Iodide SCHEMBL3989389 | 0.79 | ADORA1 (0.65) | ADORA1FBP1ALDH1A1SMN1; SMN2 | |
| Iodide SCHEMBL3986093 | 0.79 | ADORA1 (0.62) | ADORA1FBP1ALDH1A1SMN1; SMN2 | |
| Iodide SCHEMBL3994525 | 0.78 | ADORA1 (0.49) | ADORA1ALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL3989391 | 0.78 | ADORA1 (0.61) | ADORA1FBP1ALDH1A1GAASMN1; SMN2 | |
| Iodide SCHEMBL3992012 | 0.75 | ADORA1 (0.52) | ADORA1FBP1ALDH1A1POLBGAA | |
| SCHEMBL13944126 | 0.75 | MAPT (0.46) | ADORA1ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485655-B2 | 2-Aminothiazole allosteric enhancers of A1 adenosine receptors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885FBP1 851/4885MYC 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.